| Ytd | -3.48% | |
| 1y | -40.94% |
| Open | 0.93 | Prev Close | 0.93 | Low | 0.93 | High | 0.94 | Mkt Cap | 9.53M |
| Vol | 583.00 | Avg Vol | 97.15K | EPS | -0.72 | P/E | -1.29 | Forward P/E | -1.22 |
| Beta | 1.41 | Short Ratio | 0.12 | Inst. Own | 6.94% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 1.06 | 200-d Avg | 1.10 | 1yr Est | 8.00 |
COCP News
BOTHELL, Wash. , June 03, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma Inc. (Nasdaq: COCP) ("Cocrystal"
Novel, potent pan-viral inhibitors targeting the viral replication complex are under development for
BOTHELL, Wash., May 15, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal”
BOTHELL, Wash., April 30, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal
US stocks fall, Dow drops over 50 points, real estate shares rise, Acuity Inc. shares decline, Sky Q
US stocks traded lower on Thursday, with the Nasdaq falling 1%. Energy shares rose, while consumer d
The company said the FDA's Fast Track designation is intended to facilitate development and expedite
FDA Fast Track designation supports accelerated development and expedites regulatory review Noroviru
Phase 1b norovirus challenge study is underway at Emory University School of Medicine CDI-988 is the
Cocrystal Pharma (NASDAQ: COCP - Get Free Report) is anticipated to issue its results before the mar
Cocrystal Pharma, Inc. (NASDAQ: COCP - Get Free Report)'s stock price traded up 2% during mid-day tr
CDI-988 is a direct-acting, oral antiviral being developed for norovirus Norovirus challenge study i
BOTHELL, Wash., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal”
Cocrystal Pharma, Inc. (NASDAQ: COCP - Get Free Report) Director Phillip Md Et Al Frost bought 20,00
BOTHELL, Wash., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal”
BOTHELL, Wash., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal”
Received FDA IND clearance to evaluate CDI-988 as both norovirus preventive and treatment Expects to
Investment by Directors and Management demonstrates confidence in the Company Potential for an addit
BOTHELL, Wash., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc.
BOTHELL, Wash., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal”
$4.7 million upfront with up to an additional approximately $8.3 million of potential aggregate gros
On Friday morning, 446 companies hit new 52-week lows.
On Tuesday, 838 companies hit new 52-week lows.
On Friday, 404 stocks made new 52-week lows.
Monday saw 825 companies set new 52-week lows.
On Thursday, 1076 companies hit new 52-week lows.
On Friday, 1043 companies hit new 52-week lows.
Tuesday's session saw 729 companies set new 52-week lows.